Senti Biosciences Holdings (SNTI) EBT (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly EBT of -$117.4 million for Q4 2025, down 19.9% year-over-year from -$146.5 million in Q4 2024, and down 341.37% quarter-over-quarter from -$26.6 million in Q3 2025.
Senti Biosciences Holdings (SNTI) EBT (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' EBT history runs 5 years deep, the most recent figure standing at -$117.4 million for Q4 2025.
- In Q4 2025, EBT fell 19.9% year-over-year to -$117.4 million; the TTM figure through Dec 2025 stood at -$223.9 million (up 12.23% YoY), while the FY2025 annual figure was -$167.5 million, down 17.34% from the prior year.
- EBT for Q4 2025 stood at -$117.4 million, down from -$26.6 million in the prior quarter.
- The five-year high for EBT was -$1178.0 in Q1 2021, with the low at -$117.4 million in Q4 2025.
- The 5-year median for EBT is -$60.6 million (2022), against an average of -$54.1 million.
- The sharpest annual moves came in 2022 and 2024: EBT plunged 996066.21% in 2022, then jumped 71.72% in 2024.
- Senti Biosciences Holdings' EBT stood at -$33.6 million in 2021, then tumbled by 75.31% to -$58.8 million in 2022, then slumped by 35.87% to -$80.0 million in 2023, then slipped by 22.42% to -$97.9 million in 2024, then declined by 19.9% to -$117.4 million in 2025.
- Business Quant data shows SNTI's EBT at -$117.4 million in Q4 2025, -$26.6 million in Q3 2025, and -$58.4 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | 177.81 Mn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | -264.70 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -11.37 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 81.49 Mn |
| 10 | Senti Biosciences Holdings | 11.81 Mn | 11.81 Mn | - | -14.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -117.36 Mn |
| Sep 30, 2025 | -26.59 Mn |
| Jun 30, 2025 | -58.45 Mn |
| Mar 31, 2025 | -21.55 Mn |
| Dec 31, 2024 | -97.88 Mn |
| Sep 30, 2024 | -27.79 Mn |
| Jun 30, 2024 | -62.37 Mn |
| Mar 31, 2024 | -67.11 Mn |
| Dec 31, 2023 | -79.95 Mn |
| Sep 30, 2023 | -98.26 Mn |
| Jun 30, 2023 | -71.35 Mn |
| Mar 31, 2023 | -72.87 Mn |
| Dec 31, 2022 | -58.85 Mn |
| Sep 30, 2022 | -74.42 Mn |
| Jun 30, 2022 | -82.14 Mn |
| Mar 31, 2022 | -11.73 Mn |
| Dec 31, 2021 | -33.57 Mn |
| Sep 30, 2021 | -11.42 Mn |
| Jun 30, 2021 | -9.00 Mn |
| Mar 31, 2021 | -1,178.00 |